OBJECTIVES: We sought to further define the role of sarcomere mutations in dilated cardiomyopathy (DCM) and associated clinical phenotypes. BACKGROUND: Mutations in several contractile proteins contribute to DCM, but definitive evidence for the roles of most sarcomere genes remains limited by the lack of robust genetic support. METHODS: Direct sequencing of 6 sarcomere genes was performed on 334 probands with DCM. A novel D230N missense mutation in the gene encoding alpha-tropomyosin (TPM1) was identified. Functional assessment was performed by the use of an in vitro reconstituted sarcomere complex to evaluate ATPase regulation and Ca(2+) affinity as correlates of contractility. RESULTS: TPM1 D230N segregated with DCM in 2 large unrelated families. This mutation altered an evolutionarily conserved residue and was absent in >1,000 control chromosomes. In vitro studies demonstrated major inhibitory effects on sarcomere function with reduced Ca(2+) sensitivity, maximum activation, and Ca(2+) affinity compared with wild-type TPM1. Clinical manifestations ranged from decompensated heart failure or sudden death in those presenting early in life to asymptomatic left ventricular dysfunction in those diagnosed during adulthood. Notably, several affected infants had remarkable improvement. CONCLUSIONS: Genetic segregation in 2 unrelated families and functional analyses conclusively establish a pathogenic role for TPM1 mutations in DCM. In vitro results demonstrate contrasting effects of DCM and hypertrophic cardiomyopathy mutations in TPM1, suggesting that specific functional consequences shape cardiac remodeling. Along with previous reports, our data support a distinctive, age-dependent phenotype with sarcomere-associated DCM where presentation early in life is associated with severe, sometimes lethal, disease. These observations have implications for the management of familial DCM. Copyright (c) 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
OBJECTIVES: We sought to further define the role of sarcomere mutations in dilated cardiomyopathy (DCM) and associated clinical phenotypes. BACKGROUND: Mutations in several contractile proteins contribute to DCM, but definitive evidence for the roles of most sarcomere genes remains limited by the lack of robust genetic support. METHODS: Direct sequencing of 6 sarcomere genes was performed on 334 probands with DCM. A novel D230N missense mutation in the gene encoding alpha-tropomyosin (TPM1) was identified. Functional assessment was performed by the use of an in vitro reconstituted sarcomere complex to evaluate ATPase regulation and Ca(2+) affinity as correlates of contractility. RESULTS: TPM1 D230N segregated with DCM in 2 large unrelated families. This mutation altered an evolutionarily conserved residue and was absent in >1,000 control chromosomes. In vitro studies demonstrated major inhibitory effects on sarcomere function with reduced Ca(2+) sensitivity, maximum activation, and Ca(2+) affinity compared with wild-type TPM1. Clinical manifestations ranged from decompensated heart failure or sudden death in those presenting early in life to asymptomatic left ventricular dysfunction in those diagnosed during adulthood. Notably, several affected infants had remarkable improvement. CONCLUSIONS: Genetic segregation in 2 unrelated families and functional analyses conclusively establish a pathogenic role for TPM1 mutations in DCM. In vitro results demonstrate contrasting effects of DCM and hypertrophic cardiomyopathy mutations in TPM1, suggesting that specific functional consequences shape cardiac remodeling. Along with previous reports, our data support a distinctive, age-dependent phenotype with sarcomere-associated DCM where presentation early in life is associated with severe, sometimes lethal, disease. These observations have implications for the management of familial DCM. Copyright (c) 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Authors: M Kamisago; S D Sharma; S R DePalma; S Solomon; P Sharma; B McDonough; L Smoot; M P Mullen; P K Woolf; E D Wigle; J G Seidman; C E Seidman Journal: N Engl J Med Date: 2000-12-07 Impact factor: 91.245
Authors: C Redwood; K Lohmann; W Bing; G M Esposito; K Elliott; H Abdulrazzak; A Knott; I Purcell; S Marston; H Watkins Journal: Circ Res Date: 2000-06-09 Impact factor: 17.367
Authors: S Morimoto; Q-W Lu; K Harada; F Takahashi-Yanaga; R Minakami; M Ohta; T Sasaguri; I Ohtsuki Journal: Proc Natl Acad Sci U S A Date: 2002-01-02 Impact factor: 11.205
Authors: Joachim P Schmitt; Mitsuhiro Kamisago; Michio Asahi; Guo Hua Li; Ferhaan Ahmad; Ulrike Mende; Evangelia G Kranias; David H MacLennan; J G Seidman; Christine E Seidman Journal: Science Date: 2003-02-28 Impact factor: 47.728
Authors: Ray E Hershberger; Joann Lindenfeld; Luisa Mestroni; Christine E Seidman; Matthew R G Taylor; Jeffrey A Towbin Journal: J Card Fail Date: 2009-03 Impact factor: 5.712
Authors: Madhusudhan Tarigopula; Robert T Davis; Paul T Mungai; David M Ryba; David F Wieczorek; Conrad L Cowan; Jonathan D Violin; Beata M Wolska; R John Solaro Journal: Cardiovasc Res Date: 2015-06-04 Impact factor: 10.787
Authors: Chehade N Karam; Chad M Warren; Sudarsan Rajan; Pieter P de Tombe; David F Wieczorek; R John Solaro Journal: J Muscle Res Cell Motil Date: 2011-01-09 Impact factor: 2.698
Authors: Jolanda van der Velden; Carolyn Y Ho; Jil C Tardiff; Iacopo Olivotto; Bjorn C Knollmann; Lucie Carrier Journal: Cardiovasc Res Date: 2015-01-28 Impact factor: 10.787